About 10% of all cases of breast cancer are related to genetic predisposition or family history, with variances by country and ethnicity. The most common germline mutations associated with breast cancer are in the BRCA1 and BRCA2 genes, with an average cumulative lifetime risk of about 70%. A high proportion of breast cancer cases might be attributed to pregnancy-associated factors, hormonal therapy, lifestyle factors (ie, obesity, physical inactivity, alcohol intake, low-fibre diet, and smoking), and other risk factors In high-income countries, more than a third of cases of breast cancer seem to be preventable through lifestyle changes.
Breast cancer is very heterogeneous, and clinically divided into three main subtypes by hormone receptor (ER and PR) and HER2 (ERBB2) status.
Despite being rare, breast cancer also affects men, in Portugal, about 1% of breast cancers are in men.
Over the years, there has been a continuous investigation: new data are discovered about its causes and new ways of preventing, detecting and treating. All work with the objective of improving the quality of life, chances of cure, and how to diminish the psychological and social burden of this disease.
Future research in breast cancer will focus not only on new drugs, but even more on the individualization of therapy for every single tumor in every single patient.
Status | Study | Conditions | Interventions | Locations |
Recruiting | [18F] F-GLN by PET/CT in Breast Cancer | Breast Cancer | Drug: Fluoroglutamine [18F]F-GLN | University of Pennsylvania Philadelphia, Pennsylvania, United States |
Recruiting | Elevate! : An Elderly Breast Cancer Cohort Study | Breast Cancer | Behavioral: Observational cohort |
|
Recruiting | Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | Breast Cancer |
|
|
Recruiting | Topical Calcipotriene Treatment for Breast Cancer Immunoprevention | Breast Cancer |
|
Massachusetts General Hospital Boston, Massachusetts, United States |
Recruiting | SABER Study for Selected Early Stage Breast Cancer | Breast Cancer | Radiation: Stereotactic Ablative Breast Radiotherapy | University of Miami Miami, Florida, United States |
Recruiting | Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer | Breast Cancer | Other: Prosigna PAM-50 assay | Dana-Farber Cancer Institute Boston, Massachusetts, United States |
Recruiting | What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer? | Breast Cancer | Diagnostic Test: screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice |
|
Recruiting | Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. | Breast Cancer |
|
Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States |
Recruiting | GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases | Breast Cancer |
|
Dana-Farber Cancer Institute Boston, Massachusetts, United States |
Recruiting | Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Breast Cancer | Drug: Talazoparib | Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States |
Call us now if you are in a medical emergency need, we will reply swiftly and provide you with a medical aid.